Siris S G, Morgan V, Fagerstrom R, Rifkin A, Cooper T B
Arch Gen Psychiatry. 1987 Jun;44(6):533-9. doi: 10.1001/archpsyc.1987.01800180043008.
The efficacy of adjunctive imipramine hydrochloride treatment for syndromally defined postpsychotic depression was assessed in a six-week, double-blind, placebo-controlled study. All patients had been diagnosed as having schizophrenia or schizoaffective disorder, all were receiving stable doses of fluphenazine decanoate, and all had received benztropine mesylate in an attempt to rule out neuroleptic-induced akinesia. Patients randomized to imipramine therapy fared significantly better in terms of their global improvement and in terms of individual symptoms that are components of the depression syndrome. There were no significant differences in outcome psychosis ratings or side effects. This study indicates the existence of an identifiable syndrome of secondary depression in this patient group that is likely to respond favorably to treatment with adjunctive imipramine.
在一项为期六周的双盲、安慰剂对照研究中，评估了辅助使用盐酸丙咪嗪治疗综合征性定义的精神病后抑郁的疗效。所有患者均被诊断患有精神分裂症或分裂情感性障碍，均接受稳定剂量的癸酸氟奋乃静治疗，并且均接受了甲磺酸苯扎托品治疗，以试图排除抗精神病药物引起的运动不能。随机接受丙咪嗪治疗的患者在总体改善以及抑郁综合征组成部分的个体症状方面表现明显更好。在结局性精神病评分或副作用方面没有显著差异。这项研究表明，该患者群体中存在一种可识别的继发性抑郁综合征，可能对辅助使用丙咪嗪治疗有良好反应。
